Top

Open Access 07-03-2024 | Hypertension | Original Paper

Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomes

Authors: Hussam Al Ghorani, Saarraaken Kulenthiran, Lucas Lauder, Michael Johannes Maria Recktenwald, Juliane Dederer, Michael Kunz, Felix Götzinger, Sebastian Ewen, Christian Ukena, Michael Böhm, Felix Mahfoud

Published in: Clinical Research in Cardiology

Abstract

Background

Randomized sham-controlled trials have confirmed the efficacy and safety of catheter-based renal denervation in hypertension. Data on the very long-term effects of renal denervation are scarce.

Aims

This study evaluates the 10-year safety and efficacy of renal denervation in resistant hypertension.

Methods

This prospective single-center study included patients with resistant hypertension undergoing radio-frequency renal denervation between 2010 and 2012. Office blood pressure, 24-h ambulatory blood pressure, antihypertensive medication, color duplex sonography, and renal function were assessed after 1-, 2- and 10-years.

Results

Thirty-nine patients completed the 10-year follow-up (mean follow-up duration 9.4 ± 0.7 years). Baseline office and 24-h ambulatory systolic blood pressure were 164 ± 23 mmHg and 153 ± 16 mmHg, respectively. After 10 years, 24-h ambulatory and office systolic blood pressure were reduced by 16 ± 17 mmHg (P < 0.001) and 14 ± 23 mmHg (P = 0.001), respectively. The number of antihypertensive drugs remained unchanged from 4.9 ± 1.4 to 4.5 ± 1.2 drugs (P = 0.087). The estimated glomerular filtration rate declined within the expected range from 69 (95% CI 63 to 74) to 60 mL/min/1.73m² (95% CI 53 to 68; P < 0.001) through 10-year follow-up. Three renal artery interventions were documented for progression of pre-existing renal artery stenosis in two patients and one patient with new-onset renal artery stenosis. No other adverse events were observed during the follow-up.

Conclusion

Renal denervation was safe and sustainedly reduced ambulatory and office blood pressure out to 10 years in patients with resistant hypertension.

Graphical abstract

Left panel, Change in 24-h and office SBP. Right panel, eGFR over time. SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate.

Available only for authorised users

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Circ 138:e484–e594. https://doi.org/10.1161/CIR.0000000000000596CrossRef

Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M et al (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 39:3021–3104. https://doi.org/10.1093/eurheartj/ehy339CrossRefPubMed

Egan BM, Li J, Sutherland SE, Rakotz MK, Wozniak GD (2021) Hypertension control in the United States 2009 to 2018: factors underlying falling control rates during 2015 to 2018 across age- and race-ethnicity groups. Hypertension 78:578–587. https://doi.org/10.1161/HYPERTENSIONAHA.120.16418CrossRefPubMed

Johns EJ, Kopp UC, Dibona GF (2011) Neural control of renal function. Compr Physiol 1:731–767. https://doi.org/10.1002/cphy.c100043CrossRefPubMed

Lauder L, Azizi M, Kirtane AJ, Böhm M, Mahfoud F (2020) Device-based therapies for arterial hypertension. Nat Rev Cardiol 17:614–628. https://doi.org/10.1038/s41569-020-0364-1CrossRefPubMed

Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE et al (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 395:1444–1451. https://doi.org/10.1016/S0140-6736(20)30554-7CrossRefPubMed

Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S et al (2018) Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 391:2346–2355. https://doi.org/10.1016/S0140-6736(18)30951-6CrossRefPubMed

Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J et al (2018) Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 6736:1–11. https://doi.org/10.1016/S0140-6736(18)31082-1CrossRef

Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD et al (2019) Six-month results of treatment-blinded medication titration for hypertension control after randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO trial. CIRC J 139:2542–2553. https://doi.org/10.1161/CIRCULATIONAHA.119.040451CrossRef

10.

Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T et al (2021) Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 397:2476–2486. https://doi.org/10.1016/S0140-6736(21)00788-1CrossRefPubMed

11.

Ahmad Y, Kane C, Arnold AD, Cook CM, Keene D, Shun-Shin M et al (2022) Randomized blinded placebo-controlled trials of renal sympathetic denervation for hypertension: a meta-analysis. Cardiovasc Revasc Med 34:112–118. https://doi.org/10.1016/j.carrev.2021.01.031CrossRefPubMedPubMedCentral

12.

Syed M, Osman M, Alhamoud H, Saleem M, Munir MB, Kheiri B et al (2021) The state of renal sympathetic denervation for the management of patients with hypertension: a systematic review and meta-analysis. Catheter Cardiovasc Interv 97:E438–E445. https://doi.org/10.1002/ccd.29384CrossRefPubMed

13.

Al GH, Götzinger F, Böhm M, Mahfoud F (2022) Arterial hypertension- Clinical trials update 2021. Nutr Metab Cardiovasc Dis 32:21–31. https://doi.org/10.1016/j.numecd.2021.09.007CrossRefPubMed

14.

Mahfoud F, Mancia G, Schmieder RE, Ruilope L, Narkiewicz K, Schlaich M et al (2022) Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range. J Am Coll Cardiol 80(20):1871–1880. https://doi.org/10.1016/j.jacc.2022.08.802CrossRefPubMed

15.

Kario K, Mahfoud F, Kandzari DE, Townsend RR, Weber MA, Schmieder RE et al (2022) Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res 280–8. https://doi.org/10.1038/s41440-022-01042-8

16.

Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE et al (2022) Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 399(10333):1401–1410. https://doi.org/10.1016/S0140-6736(22)00455-XCrossRefPubMed

17.

Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J et al (2022) Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention 18(8):E677–E685. https://doi.org/10.4244/EIJ-D-22-00305CrossRefPubMedPubMedCentral

18.

Al Ghorani H., Kulenthiran S., Recktenwald MJM., Lauder L, Kunz M, Götzinger F et al (2023) 10-Year Outcomes of Catheter-Based Renal Denervation in Patients With Resistant Hypertension. J Am Coll Cardiol 81(5):517–9. https://doi.org/10.1016/j.jacc.2022.11.038

19.

Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006CrossRefPubMedPubMedCentral

20.

Sesa-Ashton G, Nolde JM, Muente I, Carnagarin R, Lee R, Macefield VG et al (2023) Catheter-based renal denervation: 9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension. Hypertension 80(4):811–819. https://doi.org/10.1161/HYPERTENSIONAHA.122.20853CrossRefPubMed

21.

Polonia J, Azevedo A, Monte M, Silva JA, Bertoquini S (2017) Annual deterioration of renal function in hypertensive patients with and without diabetes. Vasc Health Risk Manag 13:231–237. https://doi.org/10.2147/VHRM.S135253CrossRefPubMedPubMedCentral

22.

Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, Wei FF et al (2019) Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA 322:409–420. https://doi.org/10.1001/jama.2019.9811CrossRefPubMedPubMedCentral

23.

Staplin N, Sierra A De, Ruilope LM, Emberson JR, Vinyoles E, Gorostidi M et al (2023) Relationship between clinic and ambulatory blood pressure and mortality : an observational cohort study in 59 124 patients. 6736(23):1–10. https://doi.org/10.1016/S0140-6736(23)00733-X

24.

Weber MA, Schmieder RE, Kandzari DE, Townsend RR, Mahfoud F, Tsioufis K et al (2022) Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial. Clin Res Cardiol 111(11):1269–1275. https://doi.org/10.1007/s00392-022-02064-5CrossRefPubMedPubMedCentral

25.

Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP et al (2015) Reinnervation following catheter-based radio-frequency renal denervation. Exp Physiol 100:485–490. https://doi.org/10.1113/expphysiol.2014.079871CrossRefPubMed

26.

Singh RR, McArdle ZM, Iudica M et al (2019) Sustained decrease in blood pressure and reduced anatomical and functional reinnervation of renal nerves in hypertensive sheep 30 months after catheter-based renal denervation. Hypertension 73:718–727. https://doi.org/10.1161/HYPERTENSIONAHA.118.12250CrossRefPubMed

27.

Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP et al (2015) Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension 65:393–400. https://doi.org/10.1161/HYPERTENSIONAHA.114.04176

28.

Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K et al (2014) Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383:622–629. https://doi.org/10.1016/S0140-6736(13)62192-CrossRefPubMed

29.

Mahfoud F, Renkin J, Sievert H, Bertog S, Ewen S, Böhm M et al (2020) Alcohol-mediated renal denervation using the peregrine system infusion catheter for treatment of hypertension. JACC Cardiovasc Interv 13:471–484. https://doi.org/10.1016/j.jcin.2019.10.048CrossRefPubMed

30.

Townsend RR, Walton A, Hettrick DA, Hickey GL, Weil J, Sharp ASP et al (2020) Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention 16:89–96CrossRefPubMed

31.

Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L et al (2019) Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 40:3474–3482. https://doi.org/10.1093/eurheartj/ehz118CrossRefPubMedPubMedCentral

32.

Vupputuri S, Batuman V, Muntner P, Bazzano LA, Lefante JJ, Whelton PK et al (2003) Effect of blood pressure on early decline in kidney function among hypertensive men. Hypertension 42:1144–1149. https://doi.org/10.1161/01.HYP.0000101695.56635.31CrossRefPubMed

33.

Chowdhury EK, Langham RG, Ademi Z, Owen A, Krum H, Wing LMH et al (2015) Rate of change in renal function and mortality in elderly treated hypertensive patients. Clin J Am Soc Nephrol 10:1154–1161. https://doi.org/10.2215/CJN.07370714CrossRefPubMedPubMedCentral

34.

Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V et al (2012) Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol 7:401–408. https://doi.org/10.2215/CJN.07650711CrossRefPubMed

35.

Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al (2000) Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 36:646–661. https://doi.org/10.1053/ajkd.2000.16225CrossRefPubMed

36.

Pontremoli R, Viazzi F, Martinoli C, Ravera M, Nicolella C, Berruti V et al (1999) Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrol Dial Transplant 14(2):360–365. https://doi.org/10.1093/ndt/14.2.360CrossRefPubMed

37.

Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C et al (2012) Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 60(2):419–424. https://doi.org/10.1161/HYPERTENSIONAHA.112.193870CrossRefPubMed

38.

Böhm M, Townsend RR, Kario K, Kandzari D, Mahfoud F, Weber MA et al (2020) Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medicat. Clin Res Cardiol 109:289–302. https://doi.org/10.1007/s00392-020-01595-zCrossRefPubMedPubMedCentral

39.

Ewen S, Meyer MR, Cremers B, Laufs U, Helfer AG, Linz D et al (2015) Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol 104:1097–1105. https://doi.org/10.1007/s00392-015-0905-5CrossRefPubMed

Title: Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomes
Authors: Hussam Al Ghorani
Saarraaken Kulenthiran
Lucas Lauder
Michael Johannes Maria Recktenwald
Juliane Dederer
Michael Kunz
Felix Götzinger
Sebastian Ewen
Christian Ukena
Michael Böhm
Felix Mahfoud
Publication date: 07-03-2024
Publisher: Springer Berlin Heidelberg
Keywords: Hypertension
Hypertension
Neurotomy
Renal Artery Stenosis
Renal Artery Stenosis
Published in: Clinical Research in Cardiology
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-024-02417-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomes

Abstract

Background

Aims

Methods

Results

Conclusion

Graphical abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aims

Methods

Results

Conclusion

Graphical abstract

Please log in to get access to this content